Search - tctmd.com

Displaying 161 - 174 of 174

Sort: Relevancy | Date

News Conference News TCT 2012

PARTNER: Benefits of TAVR Sustained Out to 3 Years

October 25, 2012

News Conference News TCT 2012

PARTNER Shows Continued Benefits of TAVR, but STACCATO Introduces Questions About Transapical Use

October 23, 2012

News Conference News TCT 2012

Successful Device Innovation Focuses on Clinical Needs, Multidisciplinary Approach

October 23, 2012

News Conference News TCT 2012

PARTNER Analyses Provide Important Insights into TAVR

October 22, 2012

News Conference News

PARTNER Cohort B: TAVR Remains Superior to Standard Therapy at 2 Years

November 09, 2011

News Conference News

Recovery in Japan Ongoing, But Help Still Needed

November 09, 2011

News Conference News

Caution Urged in Widespread Adoption of TAVR

November 08, 2011

News Conference News

No Change Seen in European TAVR Clinical Use Patterns

November 06, 2011

Video

» Topical Discussion

First Insights on the PARTNER 3 Trial 5-year Data

November 2, 2023

Video

» Interview

PARTNER 3: Two-Year Economic Outcomes From a Randomized Trial of TAVR vs. SAVR in Patients at Low Surgical Risk

November 4, 2021

Video

» Interview

Dr. C. Michael Gibson Talks With Dr. Suzanne Baron About the Cost-Effectiveness Analysis from COAPT and Health Status Outcomes from PARTNER 3

September 29, 2019

Video

PARTNER 3: Health Status Outcomes From a Randomized Trial of Transcatheter vs. Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Low Surgical Risk

September 29, 2019

Video

» Interview

Dr. C. Michael Gibson Talks With Dr. Raj Makkar About the PARTNER 3 Low-Risk Computed Tomography Substudy: Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves

September 26, 2019

Video

» Interview

TCT 2017: Dr. C. Michael Gibson talks with Dr. David Cohen about PARTNER 2A and SAPIEN 3 Cost-effectiveness

May 11, 2018

Advertisement

PARTNER: Benefits of TAVR Sustained Out to 3 Years

PARTNER Shows Continued Benefits of TAVR, but STACCATO Introduces Questions About Transapical Use

Successful Device Innovation Focuses on Clinical Needs, Multidisciplinary Approach

PARTNER Analyses Provide Important Insights into TAVR

PARTNER Cohort B: TAVR Remains Superior to Standard Therapy at 2 Years

Recovery in Japan Ongoing, But Help Still Needed

Caution Urged in Widespread Adoption of TAVR

No Change Seen in European TAVR Clinical Use Patterns

First Insights on the PARTNER 3 Trial 5-year Data

PARTNER 3: Two-Year Economic Outcomes From a Randomized Trial of TAVR vs. SAVR in Patients at Low Surgical Risk

Dr. C. Michael Gibson Talks With Dr. Suzanne Baron About the Cost-Effectiveness Analysis from COAPT and Health Status Outcomes from PARTNER 3

PARTNER 3: Health Status Outcomes From a Randomized Trial of Transcatheter vs. Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Low Surgical Risk

Dr. C. Michael Gibson Talks With Dr. Raj Makkar About the PARTNER 3 Low-Risk Computed Tomography Substudy: Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves

TCT 2017: Dr. C. Michael Gibson talks with Dr. David Cohen about PARTNER 2A and SAPIEN 3 Cost-effectiveness

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content